Welcome to our dedicated page for electroCore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on electroCore stock.
electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore, Inc. (Nasdaq: ECOR) announced the publication of a paper in Cephalalgia, detailing non-invasive vagus nerve stimulation (nVNS) as a beneficial treatment for primary headache disorders. The narrative review supports nVNS as effective for acute and preventive treatment of cluster headaches and migraines. Key opinion leaders expressed optimism that the findings will enhance awareness of gammaCore™, an nVNS device. The press release underscores electroCore’s commitment to advancing non-invasive therapies for headache management.
electroCore has provided an operating update, revealing a cash balance of $18.9 million at the end of Q2 2020. Despite the COVID-19 pandemic impacting their business, they reported revenue between $730,000 and $750,000, slightly exceeding Q1 performance. The company received an Emergency Use Authorization (EUA) for gammaCore™ to treat asthma in COVID-19 patients, with ongoing clinical trials in Spain and Pittsburgh. Additionally, orders from the VA/DoD grew, although shipped therapy months dropped due to pandemic disruptions.
electroCore, Inc. (Nasdaq: ECOR) reported an operating update for Q2 2020, citing a sequential revenue increase above $700,000, with total revenue expected between $730,000 and $750,000. The COVID-19 pandemic affected operations, leading to a decline in paid therapy months shipped to both the VA/DoD and OUS channels. However, the firm received an Emergency Use Authorization for gammaCore™ CV for asthma exacerbations related to COVID-19. Two clinical trials for gammaCore™ in COVID-19 patients are underway. Despite pandemic challenges, the company anticipates a recovery in key revenue channels.
electroCore, Inc. (Nasdaq: ECOR) will have its CEO, Dan Goldberger, participate in three investor conferences this month. The first is the Maxim Group/M-Vest COVID-19 Virtual Conference on July 16, where he'll join a panel discussing medical devices. The second conference is the Zooming with LD Micro presentation on July 21, followed by one-on-one virtual meetings. Lastly, the Canaccord Genuity 40th Annual Growth Conference is scheduled for August 11. The company focuses on non-invasive vagus nerve stimulation for treating migraines and cluster headaches.
electroCore, Inc. (Nasdaq: ECOR) plans to report its financial results for Q1 2020 on May 14, 2020, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results. The company specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapies aimed at treating conditions like migraines and cluster headaches. With a commitment to improving patient outcomes, electroCore continues to innovate in the neurology and rheumatology sectors.